WO1992018139A1 - Chimeric molecule with plasminogen activator activity and affinity for atherosclerotic plaques - Google Patents
Chimeric molecule with plasminogen activator activity and affinity for atherosclerotic plaques Download PDFInfo
- Publication number
- WO1992018139A1 WO1992018139A1 PCT/US1992/003009 US9203009W WO9218139A1 WO 1992018139 A1 WO1992018139 A1 WO 1992018139A1 US 9203009 W US9203009 W US 9203009W WO 9218139 A1 WO9218139 A1 WO 9218139A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- moiety
- plasminogen activator
- chimeric molecule
- fibrin
- plasminogen
- Prior art date
Links
- 102000001938 Plasminogen Activators Human genes 0.000 title claims abstract description 76
- 108010001014 Plasminogen Activators Proteins 0.000 title claims abstract description 76
- 229940127126 plasminogen activator Drugs 0.000 title claims abstract description 76
- 230000000694 effects Effects 0.000 title claims description 16
- 208000037260 Atherosclerotic Plaque Diseases 0.000 title claims description 14
- 102000009123 Fibrin Human genes 0.000 claims abstract description 42
- 108010073385 Fibrin Proteins 0.000 claims abstract description 42
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims abstract description 42
- 229950003499 fibrin Drugs 0.000 claims abstract description 42
- 239000000203 mixture Substances 0.000 claims abstract description 39
- 238000000034 method Methods 0.000 claims abstract description 30
- 238000011282 treatment Methods 0.000 claims abstract description 21
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 claims abstract description 11
- 229940122388 Thrombin inhibitor Drugs 0.000 claims abstract description 11
- 239000003868 thrombin inhibitor Substances 0.000 claims abstract description 11
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 49
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 49
- 108090000481 Heparin Cofactor II Proteins 0.000 claims description 37
- 229940012957 plasmin Drugs 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 12
- 238000001727 in vivo Methods 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 9
- 230000008878 coupling Effects 0.000 claims description 8
- 238000010168 coupling process Methods 0.000 claims description 8
- 238000005859 coupling reaction Methods 0.000 claims description 8
- 230000007062 hydrolysis Effects 0.000 claims description 8
- 238000006460 hydrolysis reaction Methods 0.000 claims description 8
- 238000010494 dissociation reaction Methods 0.000 claims description 7
- 230000005593 dissociations Effects 0.000 claims description 7
- 108010016626 Dipeptides Proteins 0.000 claims description 6
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 5
- 108020001507 fusion proteins Proteins 0.000 claims description 5
- 102000037865 fusion proteins Human genes 0.000 claims description 5
- 206010002388 Angina unstable Diseases 0.000 claims description 4
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 4
- 206010051055 Deep vein thrombosis Diseases 0.000 claims description 4
- 108010038807 Oligopeptides Proteins 0.000 claims description 4
- 102000015636 Oligopeptides Human genes 0.000 claims description 4
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 208000007814 Unstable Angina Diseases 0.000 claims description 4
- 206010047249 Venous thrombosis Diseases 0.000 claims description 4
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 4
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 4
- 230000002093 peripheral effect Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims description 3
- 208000021328 arterial occlusion Diseases 0.000 claims description 3
- 108010036533 arginylvaline Proteins 0.000 claims description 2
- 108010054442 polyalanine Proteins 0.000 claims description 2
- 102000004032 Heparin Cofactor II Human genes 0.000 claims 4
- NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108010054155 lysyllysine Proteins 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 abstract description 24
- 238000002560 therapeutic procedure Methods 0.000 abstract description 19
- 108090000190 Thrombin Proteins 0.000 abstract description 16
- 229960004072 thrombin Drugs 0.000 abstract description 16
- 230000002537 thrombolytic effect Effects 0.000 abstract description 10
- 239000003527 fibrinolytic agent Substances 0.000 abstract description 8
- 208000032843 Hemorrhage Diseases 0.000 abstract description 6
- 239000003146 anticoagulant agent Substances 0.000 abstract description 6
- 239000003001 serine protease inhibitor Substances 0.000 abstract description 5
- 102000008847 Serpin Human genes 0.000 abstract description 3
- 108050000761 Serpin Proteins 0.000 abstract description 3
- 208000034158 bleeding Diseases 0.000 abstract description 3
- 230000000740 bleeding effect Effects 0.000 abstract description 3
- 230000003480 fibrinolytic effect Effects 0.000 abstract description 3
- 238000010276 construction Methods 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 description 34
- 102100030500 Heparin cofactor 2 Human genes 0.000 description 32
- 102000013566 Plasminogen Human genes 0.000 description 26
- 108010051456 Plasminogen Proteins 0.000 description 26
- 229920000045 Dermatan sulfate Polymers 0.000 description 17
- 102100033571 Tissue-type plasminogen activator Human genes 0.000 description 15
- 108050006955 Tissue-type plasminogen activator Proteins 0.000 description 15
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 14
- 229940051593 dermatan sulfate Drugs 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 11
- 229960005356 urokinase Drugs 0.000 description 11
- 230000001681 protective effect Effects 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 9
- 230000009089 cytolysis Effects 0.000 description 8
- 230000002439 hemostatic effect Effects 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 230000008685 targeting Effects 0.000 description 8
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 7
- 235000004279 alanine Nutrition 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 102000012479 Serine Proteases Human genes 0.000 description 6
- 108010022999 Serine Proteases Proteins 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 108010023197 Streptokinase Proteins 0.000 description 5
- 239000012190 activator Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 229960005202 streptokinase Drugs 0.000 description 5
- 229960000103 thrombolytic agent Drugs 0.000 description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000011360 adjunctive therapy Methods 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- 230000002427 irreversible effect Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- OEANUJAFZLQYOD-CXAZCLJRSA-N (2r,3s,4r,5r,6r)-6-[(2r,3r,4r,5r,6r)-5-acetamido-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](OC)O[C@H](CO)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](OC)[C@H](C(O)=O)O1 OEANUJAFZLQYOD-CXAZCLJRSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 3
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000001732 thrombotic effect Effects 0.000 description 3
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
- 108010058207 Anistreplase Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010014522 Embolism venous Diseases 0.000 description 2
- 102000010911 Enzyme Precursors Human genes 0.000 description 2
- 108010062466 Enzyme Precursors Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 229940122055 Serine protease inhibitor Drugs 0.000 description 2
- 101710102218 Serine protease inhibitor Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000014508 negative regulation of coagulation Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000033885 plasminogen activation Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Chemical group OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 208000004043 venous thromboembolism Diseases 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- 125000001989 1,3-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([H])C([*:2])=C1[H] 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- DAQIJMOLTMGJLO-YUMQZZPRSA-N Arg-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCNC(N)=N DAQIJMOLTMGJLO-YUMQZZPRSA-N 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- XUGUHTGSMPZQIW-UHFFFAOYSA-N [[4-(4-diazonioiminocyclohexa-2,5-dien-1-ylidene)cyclohexa-2,5-dien-1-ylidene]hydrazinylidene]azanide Chemical compound C1=CC(N=[N+]=[N-])=CC=C1C1=CC=C(N=[N+]=[N-])C=C1 XUGUHTGSMPZQIW-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 102000003801 alpha-2-Antiplasmin Human genes 0.000 description 1
- 108090000183 alpha-2-Antiplasmin Proteins 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000020176 deacylation Effects 0.000 description 1
- 238000005947 deacylation reaction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZLFRJHOBQVVTOJ-UHFFFAOYSA-N dimethyl hexanediimidate Chemical compound COC(=N)CCCCC(=N)OC ZLFRJHOBQVVTOJ-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- -1 p-amidinophenyl Chemical group 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000003331 prothrombotic effect Effects 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 108010073863 saruplase Proteins 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention generally relates to agents that are useful in treating thrombotic and atherothrombotic disorders and methods of treatment using such agents.
- the invention specifically relates to compositions and methods of treatment comprising a chimeric molecule containing a plasminogen activator moiety linked to a moiety that recognizes a component in a pathologic thrombus.
- the fibrinofytic system contains a proenzyme, plasminogen, which can be converted to the active enzyme plasmin by the action of several different types of plasminogen activators.
- Plasmin is a serine protease that digests fibrin to soluble degradation products. Natural inhibition of the fibrinolytic system occurs both at the level of the plasminogen activator and at the level of plasmin (Cohen, D., Les Cahiers de la
- Plasminogen is a single chain glycoprotein converted by plasminogen activators to plasmin by cleavage of the Arg560-Val561 peptide bond.
- Plasminogen activators are serine proteases with a high specificity for plasminogen. The hydrolysis of the Arg560-Val561 peptide bond of plasminogen yields the active enzyme, plasmin.
- Streptokinase is a protein that is produced by beta.hemolytic streptococci. Streptokinase activates the fibrinofytic system indirectly by forming a complex with plasminogen. The formation of this complex exposes an active site in the plasminogen moiety, whereby the complex becomes a potent plasminogen activator.
- Anisoylated plasminogen streptokinase activator complex is an inactive derivative of the plasminogen streptokinase activator complex obtained by acylation of its active site serine. Spontaneous deacylation at physiological pH with a t of approximately 35 minutes promotes its reactivation.
- Urokinase is a serine protease composed of two polypeptide chains, connected by a disulfide bridge. Urokinase activates plasminogen directly to plasmin.
- Single chain urokinase-type plasminogen activator (scu-PA) or pro-urokinase is a single chain glycoprotein which is converted to high molecular weight two-chain urokinase by hydrolysis of the Lysl58-Ilel59 peptide bond.
- scu-PA activates fibrin-bound plasminogen much more readily than it activates circulating plasminogen.
- Tissue-type plasminogen activator is a serine protease. It occurs either as a single chain or as a two chain proteolytic derivative, t-
- PA is a poor plasminogen activator in the absence of fibrin, but it binds specifically to fibrin and activates plasminogen at the fibrin surface several hundred-fold more efficiently than it activates circulating plasminogen.
- c ⁇ -antiplasmin is a glycoprotein of the serine protease inhibitor
- Plasminogen activator inhibitor-1 is a fast acting inhibitor of t-PA and urokinase occurring at very low concentration in the blood, but which may be significantly increased in several disease states including venous thromboembolism and ischemic heart disease.
- Plasminogen activators are thrombolytic agents that convert plasminogen, the inactive proenzyme of the fibrinofytic system in blood, to plasmin. Plasmin not only dissolves the fibrin of a blood clot, but may also lead to hemorrhage by degrading normal components of the hemostatic system. Several plasminogen activators have been either used clinically or are currently under clinical investigation.
- streptokinase include streptokinase, urokinase, recombinant tissue-type plasminogen activator, anisoylated plasminogen streptokinase activator complex and single chain urokinase- type plasminogen activator (Collen D. et al, Verh. Acad. Geneeskd (Belgium) 52:191 (1990); Collen et al. Ann. Rev. Med. 39:405 (1990)).
- Single-chain urokinase-type plasminogen activator has been developed as another relatively clot- selective plasminogen activator, and it has been shown in some trials to produce less depletion of plasma fibrinogen than t-PA (Loscalzo, J., et al, Circulation 79:116 (1989)).
- the remaining plasminogen activators vary in their degree of fibrin-specificity but similarly are not absolutely selective for fibrin.
- c ⁇ -antiplasmin may be depleted by the over-production of systemic plasmin that is produced during plasminogen activator therapy using non-fibrin-specific plasminogen activators. This depletion may lead to bleeding complications during treatment.
- New developments towards further improved efficacy and fibrin- specificity of thrombolytic therapy include the use of combinations of synergistic thrombolytic agents, mutants of t-PA and scu-PA chimeric t- PA/scu-PA molecules, antibody-targeted thrombofytic agents, and/or combinations of fibrin-dissolving agents with anti-platelet strategies (Bode, C et al, Clin. Cardiol 13:315 (1990).
- Bode C et al, Science 229:165 (1985). These include chemical, immunologic, or recombinant linkage of fibrin-specific antibodies with thrombolytic agents.
- chemical conjugates between a fibrin- specific and an activator-specific antibody, and biosynthetically produced heteroduplex antibodies that are both fibrin and activator-specific could bind to fibrin and localize endogenous or exogenous activator.
- These conjugates display significantly enhanced clot-specific lysis in vitro and, in an animal model, in vivo. (Collen, D. et al, Verh. Acad.. Geneeskd (Belgium) 51:191 (1990); Collen et al Ann. Rev. Med. 39:405 (1990) ;
- the resultant molecule might combine the fibrin affinity of t-PA (which is responsible for its concentration at the clot surface) with both the enzymatic properties of scu-PA (which is responsible for its stability in plasma) and the kinetic fibrin selectivity of scu-PA.
- t-PA which is responsible for its concentration at the clot surface
- scu-PA which is responsible for its stability in plasma
- kinetic fibrin selectivity of scu-PA One such chimera has been studied in detail (Nelles, L. et al, J. Biol Chem. 262:10855 (1987)).
- this chimera has a higher fibrin affinity than scu-PA, its affinity is not as high as that of intact t-PA.
- Studies of the chimera in vivo indicate that it has maintained most of the thrombofytic potential of scu- PA, but does not appear to be a superior agent for thrombolysis (Haber, E. et al, Thromb. Haemost. 57:253 (1987)).
- a principal drawback to the therapeutic value of the available native and modified plasminogen activators is that the currently available activators cannot distinguish a pathologic thrombus from protective hemostatic plugs, the dissolution of which may also be accompanied by hemorrhage.
- Acute myocardial infarction in particular, is associated with the development of an occlusive thrombus at the site of a fissured (activated) atherosclerotic plaque in a coronary artery as a direct proximate cause of the clinical event.
- plasminogen activators i.e., tissue-type plasminogen activator, streptokinase, or urokinase-type plasminogen activators
- Numerous clinical trials have confirmed the benefits of this treatment in terms of the firm endpoints of preservation of ventricular function and improvement in mortality (ISIS-2 Study Group, Lancet 336:65 (1990); Guerin et al, NFJM 327:1613 (1990); Wilcox et al, Lancet 2:525 (1988)).
- lysis of normal protective hemostatic plugs occurs.
- This novel strategy comprises the development of a molecule which 1) activates plasminogen efficiently, 2) inhibits thrombin, and 3) is localized to a pathologic thrombus, avoiding protective hemostatic plugs.
- This molecule is useful in the treatment of a variety of atherothrombotic and thrombotic disorders. These include acute myocardial infarction, unstable angina, deep venous thrombosis, pulmonary embolism, peripheral arterial occlusion, and cerebrovascular accident.
- This novel strategy also comprises the application of adjunctive therapy wherein said therapy is adjunctive to plasminogen activation therapy and wherein the adjunctive agent inhibits thrombin and is localized to a pathologic thrombus, avoiding protective hemostatic plugs.
- the adjunctive agent is unlinked to the plasminogen activator in this mode of therapy.
- An adjunctive therapy with these characteristics is described below.
- the present invention addresses a need in the field of thrombofytic therapy to provide an effective thrombolytic agent that minimizes hemorrhagic complications.
- the present invention comprises a novel plasminogen activator molecule that activates plasminogen efficiently and is localized to a pathologic thrombus, avoiding interaction not only with systemic components of the fibrinofytic system but also with normal protective hemostatic plugs.
- the invention further comprises the use of said novel plasminogen activator molecule in thrombolytic therapy, i.e., in the treatment of atherothrombotic disorders.
- the invention further comprises the use of a thrombin .inhibiting agent which is localized to a pathologic thrombus as an adjunct to plasminogen activator therapy for the treatment of atherothrombotic disorders.
- the present invention includes compositions that comprise a chimeric molecule with a plasminogen activator moiety that does not directly bind fibrin and wherein that moiety is linked to a second moiety that targets a component that is found in pathologic thrombi but not in normal protective thrombi.
- the invention encompasses the linkage of any suitable plasminogen activator with any desired molecule that has affinity for a component found in a pathologic thrombus, but not a normal protective hemostatic plug.
- the chimeric molecule contains a moiety that has thrombin-inhibitor activity and the linkage between the moieties is hydrolyzable in vivo and is at the active site of the plasminogen activator moiety.
- low molecular weight single- chain urokinase-type plasminogen activator is linked at its serine-protease active site to heparin cofactor II by means of an anisoyl-based coupling that is hydrolyzable in vivo.
- the present invention also encompasses methods of treatment of various atherothrombotic disorders using the compositions of the present invention.
- the present invention also includes compositions wherein a plasminogen activator is used in combination with a second component wherein the second component targets a component that is found in pathologic thrombi but not in normal protective thrombi.
- This composition encompasses the use of any suitable plasminogen activator with any suitable component that has affinity for a component found in the pathologic thrombus but not in a normal protective hemostatic plug.
- the composition contains an adjunctive component that is a component added with a plasminogen. activator wherein the component is heparin cofactor II.
- the desirable plasminogen activator is administered in conjunction with the administration of the heparin cofactor II.
- the present invention also encompasses compositions and methods of treatment of various atherothrombotic disorders using the compositions of the present invention in adjunctive therapy.
- the present invention relates to chimeric molecules that contain at least two moieties: a plasminogen activator moiety and a moiety that targets the molecule to a pathologic thrombus by means of the targeting moiety having affinity for a component found in a pathologic thrombus but not in a normal clot.
- the first and second moieties are chemically linked at the active site of the plasminogen activator moiety by a linkage that is hydrolyzable in vivo.
- a linkage that is hydrolyzable in vivo By linking these two molecules chemically and using a slowly hydrolyzable active site coupling, the plasminogen activator remains inactive until localization to the thrombus has occurred, after which the plasminogen activator and the targeting moiety dissociate at physiologic pH.
- a preferred linkage between the first and second moieties is an anisoyl-based coupling that slowly hydrolyzes at physiological pH.
- An alternative linkage between the first and second moieties is a plasmin-sensitive linker domain comprising an alanine 12-mer which links the first and second moieties and which contains a plasmin sensitive bond within the 12-mer.
- the 12-mer is a 12 amino acid oligopeptide wherein all of the amino acids are alanine moieties. Plasmin will hydrolyze any peptide bond to lysine or arginine. Therefore, the placement of lysine or arginine within the 12-mer (perhaps as lys-fys or arg-val) will provide a hydrolysis site. This site facilitates the release of the plasminogen activator into the thrombus after the chimeric molecule has bound to the de ⁇ natan sulfate in the vessel wall.
- the linkage need not be at the active site and need not be degradable in vivo.
- Covalent linkage, not involving the active site, that is not degradable may be used in the invention.
- a fusion protein is formed by recombinant DNA methods, as by forming a hybrid DNA that comprises a sequence coding for a plasminogen activator linked in the same transcriptional orientation to a sequence that codes for the targeting moiety. Upon translation of the RNA, a fusion protein, containing both activities, results.
- the invention encompasses immunological linkage.
- the second moiety contains anti-thrombin activity so that at the site of the pathologic thrombus, fibrin deposition is inhibited.
- the first moiety comprises low molecular weight single chain urokinase-type plasminogen activator or a functional derivative thereof.
- Low molecular weight scu-PA will be used because it does not bind to fibrin directfy, but only exerts its relatively fibrin-selective action kineticalfy, by preferentially converting fibrin-bound glu-plasminogen to plasmin. Because this plasminogen activator does not bind directfy to fibrin, it does not by itself have an affinity for either normal protective clots or pathologic thrombi but is directed to thrombi only by means of the targeting moiety to which it is attached.
- the plasminogen activator Since the targeting moiety targets pathologic thrombi, the plasminogen activator has access only to those thrombi. Further, because this activator activates only fibrin-bound plasminogen, circulating plasminogen is not activated and thus, systemic degradation of normal components of the fibrinolytic system is avoided.
- the dermatan sulfate binding domain is isolated and linked to urokinase thereby conferring plaque specificity without thrombin-inhibiting activity.
- the present invention also relates to compositions and methods of treatment with those compositions wherein the compositions comprise a plasminogen activator and a molecule that is specific for a pathologic thrombus, said molecule having affinity for a component found in a pathologic thrombus but not in a normal clot. This molecule has thrombin inhibiting activity.
- a desired plasminogen activator is used in conjunction with heparin cofactor II.
- low molecular weight single chain urokinase type plasminogen activator or a functional derivative thereof is used in conjunction with heparin cofactor II.
- compositions comprising a desired plasminogen activator and heparin cofactor II, and therapy encompassing the use of these compositions as well as the chimeric molecules discussed above, encompass the use of specific mutants of heparin cofactor II which increase the selectivity of binding for dermatan over heparin.
- the invention is directed to, for example, the use of lysine 173 mutated to glutamine or leucine (Whinna et al, J. Biol. Chem. 266:8129 (1991)) that increases the selectivity of binding for dermatan over heparin by several hundredfold. Accordingly, the invention is directed to heparin cofactor II, not only in its native form but in its mutant forms as well, used in combination with the plasminogen activators as described above.
- mutant forms of heparin cofactor II may be linked to any desirable plasminogen activator.
- mutant forms of heparin cofactor II are linked to low molecular weight single chain urokinase-type plasminogen activator as described above, which linkage may or may not be at the active site.
- the linkage may be hydrolyzable in vivo, such as by means of the anisoyl-based coupling described above, or by means of a plasmin sensitive linker also as described above.
- mutant heparin cofactor II may be used in conjunction, where they are not linked to, plasminogen activators such as high molecular two-chain urokinase, low molecular weight two-chain urokinase, single chain t-PA or two chain t-PA
- mutant heparin cofactor II is used to form compositions for adjunctive therapy with single chain urokinase type plasminogen activator (scu-PA).
- Glu 1 3 -Leu 14 peptide bond in scu-PA It was shown to have very similar properties to those of intact scu-PA including its conversion to an active two-chain molecule by plasmin, its intrinsic plasminogen activating potential, and its ability to induce relatively fibrin-specific clot lysis in the absence of direct fibrin binding (8). In addition, it has similar thrombofytic properties to those of intact scu-PA in vivo (Stump et al, Blood 69:592 (1987)). - • A recombinant form of this molecule has been obtained (Lijnen et al, J. Biol. Chem. 263:5594 (1988)).
- the low molecular weight scu-PA is linked to the targeting moiety by chemical methods using a hydrolyzable anisoyl group bound to the serine-protease active site of scu-PA.
- the low molecular weight form of scu-PA is less readily cleared .from the circulation than is the intact native molecule, thus prolonging somewhat its plasma half-life after dissociation of the linkage.
- the plasminogen activator moiety comprises a different plasminogen activator.
- scu-PA itself, high molecular weight two-chain urokinase, low molecular weight two-chain urokinase, single chain t-PA and two-chain t-PA.
- the targeting moiety comprises heparin cofactor II.
- Heparin cofactor II is chosen because it binds to dermatan sulfate, a component associated with atherosclerotic plaques but not with normal thrombi. Plaque activation with rupture exposes dermatan sulfate, heparin cofactor II binds to the dermatan sulfate, and plasminogen activation is thus localized to the site of thrombus. At the thrombus site, heparin cofactor II also inhibits thrombin generation in a selective manner that is catalyzed by dermatan sulfate-induced conformational changes in the serine protease inhibitor
- the targeting moiety recognizes other components in a plaque, such as chondroitin sulfate or collagen type III (in atheromas, a change in the predominant form of collagen occurs from type to type) and athero- endothelial leukocyte adhesion molecule
- Human plasma contains two heparin-independent inhibitors of thrombin: antithrombin III and heparin cofactor II.
- Heparin cofactor II inhibits thrombin by formation of stable 1:1 complexes with the protease (Tollefeen et al, J. Biol. Chem. 258:6113 (1983).
- the present invention is also directed to methods of treatment using the hybrid molecules or compositions comprising a plasminogen activator as described above in conjunction with a thrombin inhibitor that specifically recognizes pathologic thrombi, such as heparin cofactor II and its mutant forms and functional derivatives.
- a thrombin inhibitor that specifically recognizes pathologic thrombi, such as heparin cofactor II and its mutant forms and functional derivatives.
- the various embodiments of the chimeric molecule or the composition comprising plasminogen activator not linked to heparin cofactor II (or other thrombus-specific thrombin inhibitor) are administered in doses sufficient to treat thrombotic and atherothrombotic diseases of animals.
- the diseases include, but are not limited to acute myocardial infarction, unstable angina, deep venous thrombosis, pulmonary embolism, peripheral arterial occlusion, and cerebrovascular accident.
- Any thrombotic or atherothrombotic disorder is potentially amenable to treatment with the chimeric molecules or with the composition comprising a plasminogen activator not linked to heparin cofactor II (or other thrombus-specific thrombin-inhibitor of the present invention).
- treating is intended the administration to subjects of the compositions of the invention for purposes which include prophylaxis, amelioration, or cure of disease.
- administer any method of treating a subject with a substance, such as orally, intranasalfy, parenterally (intravenously, intramuscularly, or subcutaneously), or rectalfy.
- administer is also intended simultaneous or sequential administration of the individual components of the present invention.
- the plasminogen activator and the thrombin inhibitor which specifically recognizes dermatan sulfate or other components of atherosclerotic plaques, may be administered at different times. Therefore, administration may be simultaneous, within minutes, or up to around 3 hours of each other. The time frame for sequential administration will depend upon the specific plasminogen activator in the composition.
- administration would be simultaneous or the thrombin inhibitor is administered just prior to the administration of the plasminogen activator.
- simultaneous or sequential "co-administration" is intended that there is a temporal overlap of the biological activities of the co-administered components.
- animal any living creature that contains components of a fibrinofytic system such that specific thrombofysis may be induced by the administration of agents of this invention.
- animals Foremost among such animals are humans; however, the invention is not intended to be so-limiting, it being within the contemplation of the present invention to apply the compositions of the invention to any and all animals which may experience the benefits of the application.
- disease is intended any deviation from or interruption of the normal structure or function of any part, organ, or system (or combination thereof) of the body that is manifested by a characteristic set of symptoms and signs.
- functional derivative of heparin cofactor II is intended, for the purpose of the invention, any protein or peptide fragment based on the sequence of heparin cofactor II and that is similar to heparin cofactor II in that it inhibits thrombin and is activated by dermatan sulfate.
- the derivatives of low molecular weight scu-PA and heparin cofactor II may be derived from the naturally-occurring molecule or synthesized chemically or by recombinant methods based on the sequence of the naturally occurring-molecule.
- chimeric molecule is intended, for the purpose for the invention, a hybrid molecule constructed to contain functional moieties from two different proteins or two different genes.
- chimeric molecule is meant a hybrid protein which possesses a moiety that has plasminogen-activating activity and a moiety that has affinity for a non-fibrin component in an atherosclerotic plaque.
- chimeric molecule is also meant a hybrid oligonucleotide that possesses a DNA sequence that encodes a protein having plasminogen-activating activity and a DNA sequence that encodes a protein having affinity for a non-fibrin component in an atherosclerotic plaque.
- mutant is intended, for the purpose of the present invention, a heparin cofactor II peptide sequence containing one or more amino acid substitutions, deletions, or insertions.
- the effect of said deletion, substitution or insertion is to increase the selectivity of binding for dermatan over heparin relative to th e selectivity of binding of the native heparin cofactor II sequence.
- Mutations can be generated by any of the routine manipulations taught in the art such as in vitro site-specific mutagenesis.
- alanine 12-mer is intended, for the purpose of the present invention, a dodecamer of alanine that links the two functional domains, i.e., the plasminogen activator moiety and the second moiety which has affinity for a non-fibrin component found in atherosclerotic plaques.
- the second moiety may be heparin cofactor II or mutants thereof.
- the alanine 12-mer is a polyalanine linkage region that has no organized structure and which allows the domain of the second moiety to be separate from the plasminogen activator moiety so that, following dissociation, the two moieties may move independently. Further, this dodecamer is the site of a plasmin sensitive covalent bond.
- plasmin sensitive covalent bond is intended, for the purpose of the present invention, a dipeptide bond wherein the dipeptide bond is covalentfy linked to and internal to the alanine dodecamer.
- the dipeptide lysine-fysine or arginine-valine in the middle of the alanine 12-mer would be sensitive to hydrolysis after having been exposed to plasmin. Any lysine or arginine bond is plasmin sensitive.
- lysine-X or arginine-X where X is any amino acid, would be plasmin sensitive, and placement of such dipeptides within the alanine dodecamer would render the dodecamer susceptible to hydrolysis with plasmin, thus separating any moieties linked by said dodecamer.
- Arginine-valine is the most common dipeptide.
- the purpose of including a plasmin sensitive linker domain is to facilitate the release of the plasminogen activator into the thrombus after the chimeric molecule has bound to the dermatan sulfate in the vessel wall.
- the chimeric protein of the invention is a single peptide wherein the functional moieties described above are chemically linked to each other through a peptide bond or other covalent linkage.
- the moieties may be directly linked to each other or a coupling or conjugating agent (peptide or non-peptide) may be inserted between the functional moieties.
- Indirect linkage may be achieved by utilizing any of the several intermolecular cross-linking reagents. (See, for example, Means, G.E. and Feeney, R.E. Chemical Modification of Proteins, Holden-Day, 1974, pp.39-43).
- N-succinimidyl 3-(2-pyridyldithio) propionate SPDP
- N-N'- (1,3- phenylene) bismalemide both are highly specific for sulfhydiyls, and form irreversible linkages
- N-N'-ethylenebis-(iodoacetamide) or other such reagent having 6 and 11 carbon methylene bridges Relatively specific for sulfhydiyl groups
- l,5-dif_uoro-2,4-dinitrobenzene forms irreversible linkages with amino and tyrosine groups
- p,p'-difluoro-m-m'- dinitrodiphenylsulfone forms irreversible cross-linkages with amino and phenolic groups
- dimethyl adipimidate specific for amino groups
- anisoyl-based coupling is intended the type of bond formed as by using the following procedure. Using a total urokinase concentration of 1 mg/ml in 0.1 M Tris-HCl, 0.9% w/v NaCl, 20% v v glycerol, pH 7.4, acylation is accomplished by incubating the solution with 1 mM p-amidinophenyl p'-anisate-HCl at 0° for 1 hr. The solution is then exhaustively dialyzed prior to storage at 4° or lyophilization (Tanizawa et al, J. Am. Chem. Soc. 99:4495 (1977); Smith et al, Nature 290:505 (1981)).
- the chimeric protein of the invention is a dipeptide wherein the functional moieties described above are not covalently linked to each other but wherein the moieties associate with each other with sufficient affinity so as to provide the protein of this embodiment to the patient's lesion in the dipeptide form.
- This association includes, but is not limited to, ionic and hydrogen bonding, immunological affinity as between antigen and cognate antibody, and affinity as between an enzyme and its substrate.
- the conditions and concentrations useful for obtaining the couples of the invention can be readily adjusted by those of skill in the art by reference to known literature or by no more than routine experimen ⁇ tation.
- the compounds of the invention can be formulated in various pharmaceutical preparations adapted for administration in manners similar to those used for other plasminogen activator compounds.
- one aspect of the invention involves pharmaceutical compositions for human beings or animals provided by using a conventional pharmaceutical carrier, diluent, and/or excipient with an effective amount of the chimeric molecule of the invention.
- compositions of the present invention may be administered by any means that provide thrombolytic activity.
- the pharmaceutical compositions of the invention can be formulated in dosage forms for oral, parenteral or rectal administration. Sohd dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
- the active compound is admixed with at least one inert diluent such as sucrose, lactose or starch.
- inert diluent such as sucrose, lactose or starch.
- Such dosage forms can also comprise, as is normal practice, additional substances other than inert diluent.
- the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with an enteric coating.
- Liquid dosage forms for oral administration include pharmaceutically accepted emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the pharmaceutical arts. Besides inert diluents, such compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents and sweetening. Compositions for rectal administration are suppositories which may contain in addition to the active substance, excipients such as cocoa butter or suppository wax.
- Suitable formulations for parenteral administration are, above all, aqueous solutions of the active compounds in water-soluble forms, for example, in the form of water-soluble salts, and also suspensions of the active compounds, such as appropriate oily injection suspensions, for which suitable lipophilic solvents are used or aqueous injection suspensions which contain substances which increase the viscosity and optionally also contain stabilizers.
- Other methods of administration can be intravenous administration, oral administration, intraperitoneal administration, intramuscular administration, and subcutaneous administration).
- the dosage of active ingredients in the composition of this invention may be varied; however, it is necessary that the amount of the active ingredient be formulated such that a suitable dosage form is obtained.
- the dosage form depends upon the desired therapeutic effect, on the route of the administration, and on the duration of the treatment. Treatment can be carried out for any period of time, depending on the severity of the disease.
- Administration dosage and frequency will depend on the age and general health condition of the patient, taking into consideration the possibility of side-effects.
- the administration will also be dependent on concurrent treatment with other drugs and patients' tolerance of the administered drug.
- the preferred percent by weight of the plasminogen activator in compositions formulated according to the present invention is in the range of approximately 0.1 - 3.0%.
- compositions of the present invention is 0.01 - 2.0 mg/kg body weight.
Abstract
The present invention is directed to compositions and methods of treatment that are useful in thrombolytic therapy. The compositions of the present invention are designed to minimize the bleeding complications that are associated with presently available thrombolytic therapy. Accordingly, the compositions comprise a chimeric molecule constructed with a plasminogen activator moiety that cannot bind to fibrin and a moiety that targets pathologic thrombi. This construction results in a molecule that has affinity only for pathologic thrombi, thus avoiding normal thrombi and circulating components of the fibrinolytic system. The plasminogen activator may be coupled to a specific thrombin inhibitor of the serpin class that will counteract thrombin generation during thrombolysis. The present invention is also directed to compositions and methods of treatment wherein the plasminogen activator is not coupled with the moiety that targets pathologic thrombi, but wherein this moiety is used as a separate adjunct for plasminogen activator therapy.
Description
TITLE OF THE INVENTION
CHE ERIC MOLECULE WITH PLASMINOGEN ACTIVATOR ACΠVΠΎ AND AFFINITY FOR ATHEROSCLEROTIC PLAQUES
Background of the Invention
1. Field of the Invention
The present invention generally relates to agents that are useful in treating thrombotic and atherothrombotic disorders and methods of treatment using such agents. The invention specifically relates to compositions and methods of treatment comprising a chimeric molecule containing a plasminogen activator moiety linked to a moiety that recognizes a component in a pathologic thrombus.
2. Description of the Background Art
Components of the Fibrinofytic System (Collen et al, Verh. Acad. Geneeskd (Belgium) 51:191 (1990); Collen D. et al. Ann. Rev. Med. 39:405 (1990)). The fibrinofytic system contains a proenzyme, plasminogen, which can be converted to the active enzyme plasmin by the action of several different types of plasminogen activators. Plasmin is a serine protease that digests fibrin to soluble degradation products. Natural inhibition of the fibrinolytic system occurs both at the level of the plasminogen activator and at the level of plasmin (Cohen, D., Les Cahiers de la
Foundation Louis Jeantet de Medicine 2:41 (1986); Bachman, F. in Thrombosis and Haemostasis Eds. Verstraete, M. et al, pp. 227 (1987); Collen, D., Thromb. Haemost. 43:11 (1980)).
Plasminogen is a single chain glycoprotein converted by plasminogen activators to plasmin by cleavage of the Arg560-Val561 peptide bond.
Plasminogen activators are serine proteases with a high specificity for plasminogen. The hydrolysis of the Arg560-Val561 peptide bond of plasminogen yields the active enzyme, plasmin.
Streptokinase is a protein that is produced by beta.hemolytic streptococci. Streptokinase activates the fibrinofytic system indirectly by forming a complex with plasminogen. The formation of this complex exposes an active site in the plasminogen moiety, whereby the complex becomes a potent plasminogen activator.
Anisoylated plasminogen streptokinase activator complex is an inactive derivative of the plasminogen streptokinase activator complex obtained by acylation of its active site serine. Spontaneous deacylation at physiological pH with a t of approximately 35 minutes promotes its reactivation.
Urokinase is a serine protease composed of two polypeptide chains, connected by a disulfide bridge. Urokinase activates plasminogen directly to plasmin. Single chain urokinase-type plasminogen activator (scu-PA) or pro-urokinase is a single chain glycoprotein which is converted to high molecular weight two-chain urokinase by hydrolysis of the Lysl58-Ilel59 peptide bond. scu-PA activates fibrin-bound plasminogen much more readily than it activates circulating plasminogen.
Tissue-type plasminogen activator (t-PA) is a serine protease. It occurs either as a single chain or as a two chain proteolytic derivative, t-
PA is a poor plasminogen activator in the absence of fibrin, but it binds specifically to fibrin and activates plasminogen at the fibrin surface several hundred-fold more efficiently than it activates circulating plasminogen. cώ-antiplasmin is a glycoprotein of the serine protease inhibitor
(serpin) superfamily. α2-antiplasmin inactivates plasmin. It forms a reversible but inactive complex which is then slowly converted into an irreversible complex. Plasminogen activator inhibitor-1 is a fast acting inhibitor of t-PA and urokinase occurring at very low concentration in the blood, but which
may be significantly increased in several disease states including venous thromboembolism and ischemic heart disease.
Plasminogen Activator Therapy
Cardiovascular disease is often complicated by thrombosis. Death or disability are often the result of this complication. Thrombolysis could beneficially affect the outcome of such cardiovascular diseases as myocardial infarction, cerebrovascular thrombosis and venous thromboembolism. Plasminogen activators are thrombolytic agents that convert plasminogen, the inactive proenzyme of the fibrinofytic system in blood, to plasmin. Plasmin not only dissolves the fibrin of a blood clot, but may also lead to hemorrhage by degrading normal components of the hemostatic system. Several plasminogen activators have been either used clinically or are currently under clinical investigation. These include streptokinase, urokinase, recombinant tissue-type plasminogen activator, anisoylated plasminogen streptokinase activator complex and single chain urokinase- type plasminogen activator (Collen D. et al, Verh. Acad. Geneeskd (Belgium) 52:191 (1990); Collen et al. Ann. Rev. Med. 39:405 (1990)).
Significant shortcomings of plasminogen activator therapy remain, however, that limit its overall effectiveness, among which is a lack of available agents with absolute selectivity for fibrin. Despite the fact that the theoretical basis upon which the biotechnical development of t-PA is grounded is its "fibrin selectivity," in actual practice t-PA is hardly selective for fibrin. Treatment with t-PA leads not only to lysis of the fibrin composing the offending thrombus, but also to depletion of plasma fibrinogen, which itself may be at least in part responsible for the hemorrhagic complications attendant to plasminogen activator therapy (Loscalzo, J., Drugs 37:191 (1989)). Single-chain urokinase-type
plasminogen activator has been developed as another relatively clot- selective plasminogen activator, and it has been shown in some trials to produce less depletion of plasma fibrinogen than t-PA (Loscalzo, J., et al, Circulation 79:116 (1989)). The remaining plasminogen activators vary in their degree of fibrin-specificity but similarly are not absolutely selective for fibrin.
Another significant shortcoming of the available plasminogen activators is the need for large doses of these activators in order to achieve therapeutic efficacy. Large doses are associated with systemic activation of plasminogen and unpredictable bleeding, cώ-antiplasmin may be depleted by the over-production of systemic plasmin that is produced during plasminogen activator therapy using non-fibrin-specific plasminogen activators. This depletion may lead to bleeding complications during treatment. New developments towards further improved efficacy and fibrin- specificity of thrombolytic therapy include the use of combinations of synergistic thrombolytic agents, mutants of t-PA and scu-PA chimeric t- PA/scu-PA molecules, antibody-targeted thrombofytic agents, and/or combinations of fibrin-dissolving agents with anti-platelet strategies (Bode, C et al, Clin. Cardiol 13:315 (1990).
Antibody-targeted thrombolytic therapy
Several alternatives to target the action of thrombolytic agents towards the thrombus with the use of fibrin-specific antibodies are presently being investigated (Haber, E. et al, Science 243:51 (1989); Dewerchin, M., Eur. J. Biochem. 285:141 (1989); Bode, C. et al, ibid;
Bode C, et al, Science 229:165 (1985). These include chemical, immunologic, or recombinant linkage of fibrin-specific antibodies with thrombolytic agents. Alternatively, chemical conjugates between a fibrin- specific and an activator-specific antibody, and biosynthetically produced
heteroduplex antibodies that are both fibrin and activator-specific, could bind to fibrin and localize endogenous or exogenous activator. These conjugates display significantly enhanced clot-specific lysis in vitro and, in an animal model, in vivo. (Collen, D. et al, Verh. Acad.. Geneeskd (Belgium) 51:191 (1990); Collen et al Ann. Rev. Med. 39:405 (1990) ;
Bode, C. et al, J. Biol Chem. 264:944 (1989); Branscomb, E.E. et al, Clin. Res. 35-.264A (1987)).
Chimers of t-PA and scu-PA
Another approach has been to construct chimeric (hybrid) molecules that contain domains of both the t-PA and scu-PA molecules.
The resultant molecule might combine the fibrin affinity of t-PA (which is responsible for its concentration at the clot surface) with both the enzymatic properties of scu-PA (which is responsible for its stability in plasma) and the kinetic fibrin selectivity of scu-PA. One such chimera has been studied in detail (Nelles, L. et al, J. Biol Chem. 262:10855 (1987)).
Although this chimera has a higher fibrin affinity than scu-PA, its affinity is not as high as that of intact t-PA. Studies of the chimera in vivo indicate that it has maintained most of the thrombofytic potential of scu- PA, but does not appear to be a superior agent for thrombolysis (Haber, E. et al, Thromb. Haemost. 57:253 (1987)).
Deposition of Fibrin at the Site of the Thrombus
In addition to the problem of fibrin-specificity and the related problem of hemorrhage, another often- noted problem with current plasminogen activator therapy is the delay in time to lysis of the thrombus (Fitzgerald et al, Proc. Nat'l Acad. Sci. 86:1585 (1989)). One reason for this delay is that platelet and thrombin activation accompany plasminogen activator therapy, thereby leading to the simultaneous and competitive
processes of fresh platelet and fibrin accrual on a dissolving thrombus leading to slower net lysis rates than would be expected if such prothrombotic processes were inhibited. Recent data support the view that inhibition of platelet function, thrombin action, or both, enhance rates of thrombolysis (Vaughan et al, Blood 73:1213 (1989); Fitzgerald et al, Proc. Nail. Acad. Sci. USA 86:1585 (1989); Am. J. Cardiol 67:1A (1991)). In addition, many investigators believe that thrombin is the primary antagonist in this schema, since it both converts fibrinogen to fibrin and is the primary platelet agonist in vivo (Eisenberg, P.R., Am. J. Cardiol 67:19A (1991)).
Specificity for Pathologic Thrombi
A principal drawback to the therapeutic value of the available native and modified plasminogen activators is that the currently available activators cannot distinguish a pathologic thrombus from protective hemostatic plugs, the dissolution of which may also be accompanied by hemorrhage. Acute myocardial infarction, in particular, is associated with the development of an occlusive thrombus at the site of a fissured (activated) atherosclerotic plaque in a coronary artery as a direct proximate cause of the clinical event. Conversion of plasma plasminogen to plasmin by the administration of pharmacologic doses of plasminogen activators (i.e., tissue-type plasminogen activator, streptokinase, or urokinase-type plasminogen activators) leads to prompt lysis of the thrombus with restoration of patency of the involved vessel. Numerous clinical trials have confirmed the benefits of this treatment in terms of the firm endpoints of preservation of ventricular function and improvement in mortality (ISIS-2 Study Group, Lancet 336:65 (1990); Guerin et al, NFJM 327:1613 (1990); Wilcox et al, Lancet 2:525 (1988)). However, in addition to lysis of the pathologic clot, lysis of normal protective hemostatic plugs occurs. There is, thus, a need for a plasminogen
activator that is selective for a pathologic thrombus and avoids normal thrombi.
Given the observations and problems discussed above, Applicants have developed a novel strategy to optimize therapy with a thrombolytic agent. This novel strategy comprises the development of a molecule which 1) activates plasminogen efficiently, 2) inhibits thrombin, and 3) is localized to a pathologic thrombus, avoiding protective hemostatic plugs.
A novel molecule with these characteristics is described below.
This molecule is useful in the treatment of a variety of atherothrombotic and thrombotic disorders. These include acute myocardial infarction, unstable angina, deep venous thrombosis, pulmonary embolism, peripheral arterial occlusion, and cerebrovascular accident.
This novel strategy also comprises the application of adjunctive therapy wherein said therapy is adjunctive to plasminogen activation therapy and wherein the adjunctive agent inhibits thrombin and is localized to a pathologic thrombus, avoiding protective hemostatic plugs.
The adjunctive agent is unlinked to the plasminogen activator in this mode of therapy. An adjunctive therapy with these characteristics is described below.
Summary of the Invention
The present invention addresses a need in the field of thrombofytic therapy to provide an effective thrombolytic agent that minimizes hemorrhagic complications. Accordingly, the present invention comprises a novel plasminogen activator molecule that activates plasminogen efficiently and is localized to a pathologic thrombus, avoiding interaction not only with systemic components of the fibrinofytic system but also with normal protective hemostatic plugs.
The invention further comprises the use of said novel plasminogen activator molecule in thrombolytic therapy, i.e., in the treatment of atherothrombotic disorders.
The invention further comprises the use of a thrombin .inhibiting agent which is localized to a pathologic thrombus as an adjunct to plasminogen activator therapy for the treatment of atherothrombotic disorders.
Accordingly, the present invention includes compositions that comprise a chimeric molecule with a plasminogen activator moiety that does not directly bind fibrin and wherein that moiety is linked to a second moiety that targets a component that is found in pathologic thrombi but not in normal protective thrombi. The invention encompasses the linkage of any suitable plasminogen activator with any desired molecule that has affinity for a component found in a pathologic thrombus, but not a normal protective hemostatic plug.
In preferred embodiments the chimeric molecule contains a moiety that has thrombin-inhibitor activity and the linkage between the moieties is hydrolyzable in vivo and is at the active site of the plasminogen activator moiety. In a specific disclosed embodiment, low molecular weight single- chain urokinase-type plasminogen activator is linked at its serine-protease active site to heparin cofactor II by means of an anisoyl-based coupling that is hydrolyzable in vivo.
The present invention also encompasses methods of treatment of various atherothrombotic disorders using the compositions of the present invention.
Accordingly, the present invention also includes compositions wherein a plasminogen activator is used in combination with a second component wherein the second component targets a component that is found in pathologic thrombi but not in normal protective thrombi. This composition encompasses the use of any suitable plasminogen activator
with any suitable component that has affinity for a component found in the pathologic thrombus but not in a normal protective hemostatic plug. In preferred embodiments the composition contains an adjunctive component that is a component added with a plasminogen. activator wherein the component is heparin cofactor II. Thus the desirable plasminogen activator is administered in conjunction with the administration of the heparin cofactor II.
The present invention also encompasses compositions and methods of treatment of various atherothrombotic disorders using the compositions of the present invention in adjunctive therapy.
Description of the Preferred Embodiments
The present invention relates to chimeric molecules that contain at least two moieties: a plasminogen activator moiety and a moiety that targets the molecule to a pathologic thrombus by means of the targeting moiety having affinity for a component found in a pathologic thrombus but not in a normal clot.
In a preferred embodiment of the present invention the first and second moieties are chemically linked at the active site of the plasminogen activator moiety by a linkage that is hydrolyzable in vivo. By linking these two molecules chemically and using a slowly hydrolyzable active site coupling, the plasminogen activator remains inactive until localization to the thrombus has occurred, after which the plasminogen activator and the targeting moiety dissociate at physiologic pH. A preferred linkage between the first and second moieties is an anisoyl-based coupling that slowly hydrolyzes at physiological pH.
An alternative linkage between the first and second moieties is a plasmin-sensitive linker domain comprising an alanine 12-mer which links the first and second moieties and which contains a plasmin sensitive bond within the 12-mer. The 12-mer is a 12 amino acid oligopeptide wherein
all of the amino acids are alanine moieties. Plasmin will hydrolyze any peptide bond to lysine or arginine. Therefore, the placement of lysine or arginine within the 12-mer (perhaps as lys-fys or arg-val) will provide a hydrolysis site. This site facilitates the release of the plasminogen activator into the thrombus after the chimeric molecule has bound to the deπnatan sulfate in the vessel wall.
The linkage need not be at the active site and need not be degradable in vivo. Covalent linkage, not involving the active site, that is not degradable may be used in the invention. For example, in alternative embodiments a fusion protein is formed by recombinant DNA methods, as by forming a hybrid DNA that comprises a sequence coding for a plasminogen activator linked in the same transcriptional orientation to a sequence that codes for the targeting moiety. Upon translation of the RNA, a fusion protein, containing both activities, results. Alternatively, the invention encompasses immunological linkage.
In a further preferred embodiment of the invention the second moiety contains anti-thrombin activity so that at the site of the pathologic thrombus, fibrin deposition is inhibited.
In a highly preferred embodiment of the present invention, the first moiety comprises low molecular weight single chain urokinase-type plasminogen activator or a functional derivative thereof. Low molecular weight scu-PA will be used because it does not bind to fibrin directfy, but only exerts its relatively fibrin-selective action kineticalfy, by preferentially converting fibrin-bound glu-plasminogen to plasmin. Because this plasminogen activator does not bind directfy to fibrin, it does not by itself have an affinity for either normal protective clots or pathologic thrombi but is directed to thrombi only by means of the targeting moiety to which it is attached. Since the targeting moiety targets pathologic thrombi, the plasminogen activator has access only to those thrombi. Further, because this activator activates only fibrin-bound plasminogen, circulating
plasminogen is not activated and thus, systemic degradation of normal components of the fibrinolytic system is avoided.
In an alternative embodiment of the invention the dermatan sulfate binding domain is isolated and linked to urokinase thereby conferring plaque specificity without thrombin-inhibiting activity.
The present invention also relates to compositions and methods of treatment with those compositions wherein the compositions comprise a plasminogen activator and a molecule that is specific for a pathologic thrombus, said molecule having affinity for a component found in a pathologic thrombus but not in a normal clot. This molecule has thrombin inhibiting activity.
In a preferred embodiment of the invention, a desired plasminogen activator is used in conjunction with heparin cofactor II. In a highly preferred embodiment of the present invention, low molecular weight single chain urokinase type plasminogen activator or a functional derivative thereof is used in conjunction with heparin cofactor II.
In further embodiments of the invention, compositions comprising a desired plasminogen activator and heparin cofactor II, and therapy encompassing the use of these compositions as well as the chimeric molecules discussed above, encompass the use of specific mutants of heparin cofactor II which increase the selectivity of binding for dermatan over heparin. The invention is directed to, for example, the use of lysine 173 mutated to glutamine or leucine (Whinna et al, J. Biol. Chem. 266:8129 (1991)) that increases the selectivity of binding for dermatan over heparin by several hundredfold. Accordingly, the invention is directed to heparin cofactor II, not only in its native form but in its mutant forms as well, used in combination with the plasminogen activators as described above.
Specifically, mutant forms of heparin cofactor II may be linked to any desirable plasminogen activator. In a preferred embodiment, mutant forms of heparin cofactor II are linked to low molecular weight single
chain urokinase-type plasminogen activator as described above, which linkage may or may not be at the active site. The linkage may be hydrolyzable in vivo, such as by means of the anisoyl-based coupling described above, or by means of a plasmin sensitive linker also as described above.
Similarly, the mutant heparin cofactor II may be used in conjunction, where they are not linked to, plasminogen activators such as high molecular two-chain urokinase, low molecular weight two-chain urokinase, single chain t-PA or two chain t-PA In a highly preferred embodiment the mutant heparin cofactor II is used to form compositions for adjunctive therapy with single chain urokinase type plasminogen activator (scu-PA).
Low Molecular Weight Single Chain Urokinase-Type Plasminogen Activator
Low molecular weight single-chain urokinase-type plasminogen activator with a molecular weight of 32,000 has been purified from the conditioned medium of a human lung adenocarcinoma cell line (Stump et al, J. Biol Chem. 261:11120 (1986)) and from monkey kidney cells (Wijngaards et al, Thromb. Res. 42:149 (1986)). This low molecular weight derivative of scu-PA was generated by specific cleavage of the
Glu1 3-Leu14 peptide bond in scu-PA. It was shown to have very similar properties to those of intact scu-PA including its conversion to an active two-chain molecule by plasmin, its intrinsic plasminogen activating potential, and its ability to induce relatively fibrin-specific clot lysis in the absence of direct fibrin binding (8). In addition, it has similar thrombofytic properties to those of intact scu-PA in vivo (Stump et al, Blood 69:592 (1987)). -• A recombinant form of this molecule has been obtained (Lijnen et al, J. Biol. Chem. 263:5594 (1988)). This recombinant has biological properties similar to those of the natural molecule.
In a preferred molecule, the low molecular weight scu-PA is linked to the targeting moiety by chemical methods using a hydrolyzable anisoyl group bound to the serine-protease active site of scu-PA. The low molecular weight form of scu-PA is less readily cleared .from the circulation than is the intact native molecule, thus prolonging somewhat its plasma half-life after dissociation of the linkage.
In alternative embodiments of the invention the plasminogen activator moiety comprises a different plasminogen activator. Examples are scu-PA itself, high molecular weight two-chain urokinase, low molecular weight two-chain urokinase, single chain t-PA and two-chain t-PA.
In a further highly preferred embodiment of the invention, the targeting moiety comprises heparin cofactor II. Heparin cofactor II is chosen because it binds to dermatan sulfate, a component associated with atherosclerotic plaques but not with normal thrombi. Plaque activation with rupture exposes dermatan sulfate, heparin cofactor II binds to the dermatan sulfate, and plasminogen activation is thus localized to the site of thrombus. At the thrombus site, heparin cofactor II also inhibits thrombin generation in a selective manner that is catalyzed by dermatan sulfate-induced conformational changes in the serine protease inhibitor
(serpin), while scu-PA activates thrombus-bound plasminogen.
In alternative embodiments, the targeting moiety recognizes other components in a plaque, such as chondroitin sulfate or collagen type III (in atheromas, a change in the predominant form of collagen occurs from type to type) and athero- endothelial leukocyte adhesion molecule
(adhesion molecules that are expressed on the surface of endothelial cells in or adjacent to atheromata).
Heparin Cofactor II
Human plasma contains two heparin-independent inhibitors of thrombin: antithrombin III and heparin cofactor II. Heparin cofactor II
inhibits thrombin by formation of stable 1:1 complexes with the protease (Tollefeen et al, J. Biol. Chem. 258:6113 (1983).
The anticoagulant activity of dermatan sulfate was first demonstrated when it was shown that this glycosaminoglycan prolonged the partial thromboplastin time in vitro (Teien et al, Thromb. Res. 8:859
(1976)). Recent research work has provided evidence that the anticoagulant activity of dermatan sulfate is mediated through heparin cofactor II (Tollefeen et al, J. Biol Chem. 258:6113 (1983)). This work demonstrated that the rate of inhibition of thrombin by purified heparin cofactor II was increased nearly one thousand-fold by the addition of dermatan sulfate. Furthermore, the addition of dermatan sulfate to plasma containing 125I- thrombin resulted in the formation of complexes between thrombin and heparin cofactor II. These observations suggested that heparin cofactor II is activated by dermatan sulfate (Salem et al, Develop. Biol Standard 67:61 (1987)). Dermatan sulfate has been shown to accumulate in natural and diet-induced atherosclerotic plaques
(Robbins et al, Am. J. Pathol 134:615 (1989)).
The present invention is also directed to methods of treatment using the hybrid molecules or compositions comprising a plasminogen activator as described above in conjunction with a thrombin inhibitor that specifically recognizes pathologic thrombi, such as heparin cofactor II and its mutant forms and functional derivatives. In preferred methods of treatment, the various embodiments of the chimeric molecule or the composition comprising plasminogen activator not linked to heparin cofactor II (or other thrombus-specific thrombin inhibitor) are administered in doses sufficient to treat thrombotic and atherothrombotic diseases of animals. The diseases include, but are not limited to acute myocardial infarction, unstable angina, deep venous thrombosis, pulmonary embolism, peripheral arterial occlusion, and cerebrovascular accident. Any thrombotic or atherothrombotic disorder is potentially amenable to treatment with the chimeric molecules or with the
composition comprising a plasminogen activator not linked to heparin cofactor II (or other thrombus-specific thrombin-inhibitor of the present invention).
By the term "treating" is intended the administration to subjects of the compositions of the invention for purposes which include prophylaxis, amelioration, or cure of disease.
By the term "administer" is intended any method of treating a subject with a substance, such as orally, intranasalfy, parenterally (intravenously, intramuscularly, or subcutaneously), or rectalfy. By the term "administer" is also intended simultaneous or sequential administration of the individual components of the present invention. For example, the plasminogen activator and the thrombin inhibitor which specifically recognizes dermatan sulfate or other components of atherosclerotic plaques, may be administered at different times. Therefore, administration may be simultaneous, within minutes, or up to around 3 hours of each other. The time frame for sequential administration will depend upon the specific plasminogen activator in the composition. Optionally, administration would be simultaneous or the thrombin inhibitor is administered just prior to the administration of the plasminogen activator. By simultaneous or sequential "co-administration" is intended that there is a temporal overlap of the biological activities of the co-administered components.
By the term "animal" is intended any living creature that contains components of a fibrinofytic system such that specific thrombofysis may be induced by the administration of agents of this invention. Foremost among such animals are humans; however, the invention is not intended to be so-limiting, it being within the contemplation of the present invention to apply the compositions of the invention to any and all animals which may experience the benefits of the application. By the term "disease" is intended any deviation from or interruption of the normal structure or function of any part, organ, or
system (or combination thereof) of the body that is manifested by a characteristic set of symptoms and signs.
By the term "functional derivative" of low molecular weight scu-PA for the purpose of the present invention is intended, any protein or peptide fragment based on the sequence of low molecular weight scu-PA and that is similar to low molecular weight scu-PA in that it activates plasminogen, does not bind fibrin directfy but binds to fibrin-bound plasminogen, and does not bind to circulating plasminogen. By the term "functional derivative" of heparin cofactor II is intended, for the purpose of the invention, any protein or peptide fragment based on the sequence of heparin cofactor II and that is similar to heparin cofactor II in that it inhibits thrombin and is activated by dermatan sulfate. The derivatives of low molecular weight scu-PA and heparin cofactor II may be derived from the naturally-occurring molecule or synthesized chemically or by recombinant methods based on the sequence of the naturally occurring-molecule.
By "chimeric molecule" is intended, for the purpose for the invention, a hybrid molecule constructed to contain functional moieties from two different proteins or two different genes. As used herein, by "chimeric molecule" is meant a hybrid protein which possesses a moiety that has plasminogen-activating activity and a moiety that has affinity for a non-fibrin component in an atherosclerotic plaque. As used herein, by "chimeric molecule" is also meant a hybrid oligonucleotide that possesses a DNA sequence that encodes a protein having plasminogen-activating activity and a DNA sequence that encodes a protein having affinity for a non-fibrin component in an atherosclerotic plaque.
By the term "mutant" is intended, for the purpose of the present invention, a heparin cofactor II peptide sequence containing one or more amino acid substitutions, deletions, or insertions. For the purpose of the invention, the effect of said deletion, substitution or insertion is to increase the selectivity of binding for dermatan over heparin relative to
th e selectivity of binding of the native heparin cofactor II sequence. Mutations can be generated by any of the routine manipulations taught in the art such as in vitro site-specific mutagenesis.
By the term "alanine 12-mer" is intended, for the purpose of the present invention, a dodecamer of alanine that links the two functional domains, i.e., the plasminogen activator moiety and the second moiety which has affinity for a non-fibrin component found in atherosclerotic plaques. The second moiety may be heparin cofactor II or mutants thereof. The alanine 12-mer is a polyalanine linkage region that has no organized structure and which allows the domain of the second moiety to be separate from the plasminogen activator moiety so that, following dissociation, the two moieties may move independently. Further, this dodecamer is the site of a plasmin sensitive covalent bond.
By "plasmin sensitive covalent bond" is intended, for the purpose of the present invention, a dipeptide bond wherein the dipeptide bond is covalentfy linked to and internal to the alanine dodecamer. For example, the dipeptide lysine-fysine or arginine-valine in the middle of the alanine 12-mer would be sensitive to hydrolysis after having been exposed to plasmin. Any lysine or arginine bond is plasmin sensitive. Therefore, lysine-X or arginine-X, where X is any amino acid, would be plasmin sensitive, and placement of such dipeptides within the alanine dodecamer would render the dodecamer susceptible to hydrolysis with plasmin, thus separating any moieties linked by said dodecamer. Arginine-valine is the most common dipeptide. The purpose of including a plasmin sensitive linker domain is to facilitate the release of the plasminogen activator into the thrombus after the chimeric molecule has bound to the dermatan sulfate in the vessel wall.
In one embodiment, the chimeric protein of the invention is a single peptide wherein the functional moieties described above are chemically linked to each other through a peptide bond or other covalent linkage. In this embodiment, the moieties may be directly linked to each
other or a coupling or conjugating agent (peptide or non-peptide) may be inserted between the functional moieties.
Indirect linkage may be achieved by utilizing any of the several intermolecular cross-linking reagents. (See, for example, Means, G.E. and Feeney, R.E. Chemical Modification of Proteins, Holden-Day, 1974, pp.39-43). Among these reagents are, for example, N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP) or N-N'- (1,3- phenylene) bismalemide (both are highly specific for sulfhydiyls, and form irreversible linkages); N-N'-ethylenebis-(iodoacetamide) or other such reagent having 6 and 11 carbon methylene bridges (relatively specific for sulfhydiyl groups); l,5-dif_uoro-2,4-dinitrobenzene (forms irreversible linkages with amino and tyrosine groups); p,p'-difluoro-m-m'- dinitrodiphenylsulfone (forms irreversible cross-linkages with amino and phenolic groups); dimethyl adipimidate (specific for amino groups); ρhenyl-2,4-disulfonylchloride (reacts principally with amino groups); hexamethylenedfisocyanate or diisothiocyanate, or azophenyl-p-diiso- cyanate (reacting principally with amino groups); glutaraldehyde (reacting with several different side chains) and bisdiazobenzidine (reacting primarily with tyrosine and histidine). These are onfy a few of several cross-linking agents that can be utilized.
By "anisoyl-based coupling" is intended the type of bond formed as by using the following procedure. Using a total urokinase concentration of 1 mg/ml in 0.1 M Tris-HCl, 0.9% w/v NaCl, 20% v v glycerol, pH 7.4, acylation is accomplished by incubating the solution with 1 mM p-amidinophenyl p'-anisate-HCl at 0° for 1 hr. The solution is then exhaustively dialyzed prior to storage at 4° or lyophilization (Tanizawa et al, J. Am. Chem. Soc. 99:4495 (1977); Smith et al, Nature 290:505 (1981)).
In another embodiment, the chimeric protein of the invention is a dipeptide wherein the functional moieties described above are not covalently linked to each other but wherein the moieties associate with each other with sufficient affinity so as to provide the protein of this
embodiment to the patient's lesion in the dipeptide form. This association includes, but is not limited to, ionic and hydrogen bonding, immunological affinity as between antigen and cognate antibody, and affinity as between an enzyme and its substrate. The conditions and concentrations useful for obtaining the couples of the invention can be readily adjusted by those of skill in the art by reference to known literature or by no more than routine experimen¬ tation.
The compounds of the invention can be formulated in various pharmaceutical preparations adapted for administration in manners similar to those used for other plasminogen activator compounds. Thus, one aspect of the invention involves pharmaceutical compositions for human beings or animals provided by using a conventional pharmaceutical carrier, diluent, and/or excipient with an effective amount of the chimeric molecule of the invention.
The compositions of the present invention may be administered by any means that provide thrombolytic activity. For example, the pharmaceutical compositions of the invention can be formulated in dosage forms for oral, parenteral or rectal administration. Sohd dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
In such sohd dosage forms, the active compound is admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms can also comprise, as is normal practice, additional substances other than inert diluent. In the case of capsule, tablets, and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with an enteric coating.
Liquid dosage forms for oral administration include pharmaceutically accepted emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the pharmaceutical arts. Besides inert diluents, such compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents and sweetening.
Compositions for rectal administration are suppositories which may contain in addition to the active substance, excipients such as cocoa butter or suppository wax.
Suitable formulations for parenteral administration are, above all, aqueous solutions of the active compounds in water-soluble forms, for example, in the form of water-soluble salts, and also suspensions of the active compounds, such as appropriate oily injection suspensions, for which suitable lipophilic solvents are used or aqueous injection suspensions which contain substances which increase the viscosity and optionally also contain stabilizers.
Other methods of administration can be intravenous administration, oral administration, intraperitoneal administration, intramuscular administration, and subcutaneous administration).
The dosage of active ingredients in the composition of this invention may be varied; however, it is necessary that the amount of the active ingredient be formulated such that a suitable dosage form is obtained. The dosage form depends upon the desired therapeutic effect, on the route of the administration, and on the duration of the treatment. Treatment can be carried out for any period of time, depending on the severity of the disease.
Administration dosage and frequency will depend on the age and general health condition of the patient, taking into consideration the possibility of side-effects. The administration will also be dependent on concurrent treatment with other drugs and patients' tolerance of the administered drug.
The preferred percent by weight of the plasminogen activator in compositions formulated according to the present invention is in the range of approximately 0.1 - 3.0%.
The preferred dosage range for compositions of the present invention is 0.01 - 2.0 mg/kg body weight.
Having now generally described the invention, the various modifications and uses that are encompassed therein will be evident to the person of ordinary skill in the art.
Claims
1. A chimeric molecule comprising a first moiety and a second moiety, wherein said first moiety has plasminogen-activator activity and does not bind to fibrin and wherein said second moiety has affinity for a non-fibrin component found in atherosclerotic plaques.
2. The chimeric molecule of claim 1 wherein said first and second moieties are dissociable from each other in vivo.
3. The chimeric molecule of claim 2 wherein said dissociation occurs by hydrolysis of a covalent bond linking the two moieties.
4. The chimeric molecule of claim 3 wherein said bond is an anisoyl-based coupling.
5. The chimeric molecule of claim 3 wherein said dissociation occurs by hydrolysis of a plasmin-sensitive covalent bond.
6. The chimeric molecule of claim 5 wherein said covalent bond is in a polyalanine 12-mer oligopeptide and wherein said oligopeptide is between and covalently linked to the first and second moieties.
7. The chimeric molecule of claim 6 wherein the covalent bond is in a lys-lys or arg-val dipeptide and wherein said dipeptide is internal to and covalently joined to said oligopeptide.
8. The chimeric molecule of claim 2 wherein said dissociation occurs at the active site of the plasminogen activator moiety.
9. The chimeric molecule of claim 1 wherein said plasminogen activator moiety is low molecular weight single chain urokinase-type plasminogen activator or a functional derivative thereof.
10. The chimeric molecule of claim 1 wherein said second moiety has thrombin inhibitor activity.
11. The chimeric molecule of claim 10 wherein said second moiety is heparin cofactor II or a functional derivative thereof.
12. A method of treating atherothrombotic disease in an animal comprising administering to said animal an effective amount of a chimeric protein comprising a first moiety and a second moiety, wherein said first moiety has plasminogen-activator activity and does not bind to fibrin and wherein said second moiety has affinity for a non-fibrin component found in atherosclerotic plaques.
13. The method of claim 12 wherein said disease is selected from the group consisting of acute myocardial infarction, unstable angina, deep venous thrombosis, pulmonary embolism, peripheral arterial occlu¬ sion, and cerebrovascular accident.
14. The method of claim 12 wherein said first and second moieties are dissociable from each other in vivo.
15. The method of claim 14 wherein said dissociation occurs by hydrolysis of a covalent bond linking the two moieties.
16. The method of claim 15 wherem said bond is an anisoyl- based coupling.
17. The method of claim 14 wherein said dissociation occurs at the active site of the plasminogen activator moiety.
18. The method of claim 12 wherein said plasminogen activator moiety is low molecular weight single chain urokinase-type plasminogen activator or a functional derivative thereof.
19. The method of claim 12 wherein said second moiety has thrombin inhibitor activity.
20. The method of claim 19 wherein said second moiety is heparin cofactor II or a functional derivative thereof.
21. A pharmaceutical composition useful in the treatment of atherothrombotic disease, said composition comprising an effective amount of the chimeric molecule of claim 1 together with a pharmaceutically acceptable carrier.
22. A composition comprising a first moiety and a second moiety wherein said first moiety has plasminogen activator activity and does not bind to fibrin and wherein said second moiety has affinity for a non-fibrin component found in atherosclerotic plaques.
23. The composition of claim 22 wherein said plasminogen activator moiety is low molecular weight, single chain urokinase-type plasminogen activator or a functional derivative thereof.
24. The composition of claim 22 wherein said second moiety has thrombin inhibitor activity.
25. The composition of claim 24 wherein said second moiety is heparin cofactor II or a mutant or a functional derivative thereof.
26. A method of treating atherothrombotic disease in an animal comprising administering to said animal an effective amount of a composition comprising a first moiety and a second moiety, wherein said first moiety has plasminogen activator activity and does not bind to fibrin and wherein said second moiety has affinity for a non-fibrin component and in atherosclerotic plaques.
27. The method of claim 26 wherein said disease is selected from the group consisting of acute myocardial infarction, unstable angina, deep venous thrombosis, pulmonary embolism, peripheral arterial occlusion, and cerebrovascular accident
28. The method of claim 26 wherein said plasminogen activator moiety is low molecular weight single-chain urokinase-type plasminogen activator or a functional derivative thereof.
29. The method of claim 26 wherein said second moiety has thrombin inhibitor activity.
30. The method of claim 29 wherein said second moiety is heparin cofactor II or a mutant or a functional derivative thereof.
31. A pharmaceutical composition useful in the treatment of atherothrombotic disease, said composition comprising an effective amount of the composition of claim 22 together with a pharmaceutically effective carrier.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68207091A | 1991-04-09 | 1991-04-09 | |
US682,070 | 1991-04-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992018139A1 true WO1992018139A1 (en) | 1992-10-29 |
Family
ID=24738080
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1992/003009 WO1992018139A1 (en) | 1991-04-09 | 1992-04-09 | Chimeric molecule with plasminogen activator activity and affinity for atherosclerotic plaques |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU1873092A (en) |
WO (1) | WO1992018139A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0669394A1 (en) * | 1993-07-15 | 1995-08-30 | Grünenthal GmbH | Bifunctional derivatives of Urokinase with improved fibrinolytic activity and Thrombin inhibiting activity |
EP0714982A2 (en) * | 1994-11-30 | 1996-06-05 | Grünenthal GmbH | Hybrid proteins with fibrinolytic and thrombin inhibiting activity |
WO2011036444A1 (en) * | 2009-09-22 | 2011-03-31 | Ximmune Ab | Heparin cofactor ii fragments with anti-inflammatory and anti-coagulant activity |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4118793A (en) * | 1977-01-12 | 1978-10-03 | International Business Machines Corporation | Gradientless propulsion of magnetic bubble domains using modulated in-plane fields |
US4285932A (en) * | 1978-09-07 | 1981-08-25 | Beecham Group Limited | Enzyme derivatives for use in the treatment of venous thrombosis |
JPS5921626A (en) * | 1982-07-28 | 1984-02-03 | Green Cross Corp:The | Urokinase-chondroitin sulfate adduct, its preparation and thrombolytic agent |
EP0284413A2 (en) * | 1987-03-27 | 1988-09-28 | Beecham Group Plc | Derivative of a fibrinolytic enzyme |
US4808405A (en) * | 1979-11-05 | 1989-02-28 | Beecham Group P.L.C. | P-anisoyl streptokinase/plasminogen complex |
US4892826A (en) * | 1988-10-11 | 1990-01-09 | Abbott Laboratories | Process for the preparation of urokinase derivatives |
WO1990011783A1 (en) * | 1989-04-03 | 1990-10-18 | Centocor, Inc. | Platelet specific immunoconjugates |
-
1992
- 1992-04-09 AU AU18730/92A patent/AU1873092A/en not_active Abandoned
- 1992-04-09 WO PCT/US1992/003009 patent/WO1992018139A1/en active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4118793A (en) * | 1977-01-12 | 1978-10-03 | International Business Machines Corporation | Gradientless propulsion of magnetic bubble domains using modulated in-plane fields |
US4285932A (en) * | 1978-09-07 | 1981-08-25 | Beecham Group Limited | Enzyme derivatives for use in the treatment of venous thrombosis |
US4808405A (en) * | 1979-11-05 | 1989-02-28 | Beecham Group P.L.C. | P-anisoyl streptokinase/plasminogen complex |
JPS5921626A (en) * | 1982-07-28 | 1984-02-03 | Green Cross Corp:The | Urokinase-chondroitin sulfate adduct, its preparation and thrombolytic agent |
JPH0215193B2 (en) * | 1982-07-28 | 1990-04-11 | Green Cross Corp | |
EP0284413A2 (en) * | 1987-03-27 | 1988-09-28 | Beecham Group Plc | Derivative of a fibrinolytic enzyme |
US4892826A (en) * | 1988-10-11 | 1990-01-09 | Abbott Laboratories | Process for the preparation of urokinase derivatives |
WO1990011783A1 (en) * | 1989-04-03 | 1990-10-18 | Centocor, Inc. | Platelet specific immunoconjugates |
Non-Patent Citations (5)
Title |
---|
BIOCHEMICAL JOURNAL, Volume 248, issued 1987, S.B. KALINDJIAN et al., "Reagents for Reversible Coupling of Proteins to the Active Centres of Trypsin-like Serine Proteinases", pages 409-413. * |
CHEST, Volume 97, No. 4, issued April 1990, J. LOSCALZO, "An Overview of Thrombolytic Agents", pages 117S-123S. * |
JOURNAL OF BIOLOGICAL CHEMISTRY, Volume 260, No. 6, issued 25 March 1985, K.A. PARKER et al., "The Protease Specificity of Heparin Cofactor II", pages 3501-05. * |
THROMBOSIS RESEARCH, Volume 61, Nos. 5/6, issued March 1991, D.P. DEBONO et al., "Local Inhibition of Thrombosis Using Urokinase Linked to a Monoclonal Antibody which Recognises Damaged Endothelium", pages 537-545. * |
WORLD PATENT INDEX ABSTRACT 003920326, accession Number 84-065870/11, "Conjugate of Urokinase with Chondroitin Sulphate useful as Thrombus Dissolving Agent"; & JP,A,59 021 626, issued 03 February 1984. * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0669394A1 (en) * | 1993-07-15 | 1995-08-30 | Grünenthal GmbH | Bifunctional derivatives of Urokinase with improved fibrinolytic activity and Thrombin inhibiting activity |
US5681721A (en) * | 1993-07-15 | 1997-10-28 | Gruenenthal Gmbh | Bifunctional urokinase variants with improved fibrinolytic characteristics and thrombin inhibiting effect |
US5747291A (en) * | 1993-07-15 | 1998-05-05 | Gruenenthal Gmbh | Bifunctional urokinase variants with improved fibrinolytic characteristics and thrombin inhibiting effect |
CN1057124C (en) * | 1993-07-15 | 2000-10-04 | 格吕伦塔尔有限公司 | Bifunctional variants of urokinase with improved fibrinolytic properties and thrombin-inhibiting activity |
EP0714982A2 (en) * | 1994-11-30 | 1996-06-05 | Grünenthal GmbH | Hybrid proteins with fibrinolytic and thrombin inhibiting activity |
EP0714982A3 (en) * | 1994-11-30 | 1999-09-08 | Grünenthal GmbH | Hybrid proteins with fibrinolytic and thrombin inhibiting activity |
US6133011A (en) * | 1994-11-30 | 2000-10-17 | Gruenenthal Gmbh | Chimeric proteins having fibrinolytic and thrombin-inhibiting properties |
WO2011036444A1 (en) * | 2009-09-22 | 2011-03-31 | Ximmune Ab | Heparin cofactor ii fragments with anti-inflammatory and anti-coagulant activity |
JP2013505030A (en) * | 2009-09-22 | 2013-02-14 | エクセルミューネ・アクチエボラーグ | Heparin cofactor II fragment having anti-inflammatory and anticoagulant activity |
US9169315B2 (en) | 2009-09-22 | 2015-10-27 | Ximmune Ab | Heparin cofactor II fragments with anti-inflammatory and anti-coagulant activity |
Also Published As
Publication number | Publication date |
---|---|
AU1873092A (en) | 1992-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5759542A (en) | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases | |
US4970159A (en) | Human tissue plasminogen activator consisting essentially of t-PA residues 160 to 527 | |
US5491129A (en) | Synthetic peptides derived from vitronectin and pharmaceutical compositions comprising them | |
US20080118933A1 (en) | Methods of screening for inhibitors of antiplasmin cleaving enzyme | |
JP2764264B2 (en) | Fibrinolytic activity enhancer | |
US5747291A (en) | Bifunctional urokinase variants with improved fibrinolytic characteristics and thrombin inhibiting effect | |
Swenson et al. | α-Fibrinogenases | |
US5951981A (en) | Thrombolytic agents with antithrombotic activity | |
WO1992018139A1 (en) | Chimeric molecule with plasminogen activator activity and affinity for atherosclerotic plaques | |
JP3329340B2 (en) | Thrombin-activated plasminogen derivative | |
US6759042B2 (en) | Use of cross-linked, covalently bound urokinase plasminogen activator (scuPA)-urokinase plasminogen activator receptor (suPAR) complex as a fibrinolytic agent | |
CA2064231A1 (en) | Combinations and methods for treating or preventing thrombotic diseases | |
US5234686A (en) | Human tissue plasminogen activator consisting essentially of t-PA residues to 160 to 527, pharmaceutical compositions and methods of treatment | |
AU2003213856B2 (en) | Peptides for regulation of urokinase (uPA) and tissue type (tPA) plasminogen activator and method of optimizing therapeutic efficacy | |
JP2904893B2 (en) | Pharmaceutical preparations | |
US7271143B1 (en) | Peptides for regulation of urokinase (uPA) and tissue type (tPA) plasminogen activator and method of optimizing therapeutic efficacy | |
JPH05500906A (en) | Treatment of thrombotic diseases | |
Robison et al. | Activators of Plasminogen | |
WO1994003488A1 (en) | Novel peptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
EX32 | Extension under rule 32 effected after completion of technical preparation for international publication |
Ref country code: UA |
|
LE32 | Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b) |
Ref country code: UA |
|
LE32 | Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b) |
Ref country code: UA |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
122 | Ep: pct application non-entry in european phase |